Title : Protein phosphatase 2B inhibitor potentiates endothelial PKC activity and barrier dysfunction.

Pub. Date : 2001 Sep

PMID : 11504680






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Pretreatment with 100 ng/ml of FK506 (a PP2B inhibitor) but not with the PP1 and PP2A inhibitors calyculin A or okadaic acid potentiated the thrombin-induced increase in PKC phosphotransferase activity. Tacrolimus coagulation factor II, thrombin Bos taurus
2 FK506 also potentiated thrombin-induced PKC-alpha but not PKC-beta phosphorylation. Tacrolimus coagulation factor II, thrombin Bos taurus
3 FK506 but not calyculin A or okadaic acid inhibited recovery from the thrombin-induced decrease in transendothelial resistance. Tacrolimus coagulation factor II, thrombin Bos taurus
4 Downregulation of PKC with phorbol 12-myristate 13-acetate rescued the FK506-mediated inhibition of recovery, which was consistent with the finding that the thrombin-induced phosphorylation of PKC-alpha was reduced during the recovery phase. Tacrolimus coagulation factor II, thrombin Bos taurus